Literature DB >> 6321358

In vitro antibody-dependent cellular cytotoxicity against human T-cell leukemia/lymphoma virus (HTLV)-producing cells.

H Miyakoshi, H Koide, T Aoki.   

Abstract

Human T-cell leukemia/lymphoma virus (HTLV)-producing cells were lysed by peripheral mononuclear cells (PMNC) from both anti-HTLV antibody-positive and -negative healthy persons in the presence of natural humoral antibodies against HTLV-related antigens (antibody-dependent cellular cytotoxicity, ADCC). PMNC from patients with T-cell leukemia, however, did not possess the positive reaction even in the presence of natural antibodies. In contrast, when the antibodies were absent, no cytotoxicity was caused by PMNC from any donors. Additionally, the complement present in the antibody-positive plasma did not contribute to humoral antibody-dependent cytotoxicity in the presence of plasma without PMNC. Therefore, ADCC against HTLV-producing cells may correlate with the prophylaxis of HTLV-induced malignancy in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6321358     DOI: 10.1002/ijc.2910330302

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.

Authors:  R A Koup; J L Sullivan; P H Levine; F Brewster; A Mahr; G Mazzara; S McKenzie; D Panicali
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

Review 2.  Immune surveillance and natural resistance: an evaluation.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 3.  A role for an HTLV-1 vaccine?

Authors:  Lee Ratner
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

4.  A protective role of HTLV-1 gp46-specific neutralizing and antibody-dependent cellular cytotoxicity-inducing antibodies in progression to adult T-cell leukemia (ATL).

Authors:  Yuetsu Tanaka; Reiko Tanaka; Naoki Imaizumi; Mariko Mizuguchi; Yoshiaki Takahashi; Masaki Hayashi; Takashi Miyagi; Junnosuke Uchihara; Kazuiku Ohshiro; Hiroaki Masuzaki; Takuya Fukushima
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.